|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Department of Veterans Affairs |
|---|---|
| Information provided by: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00018824 |
Purpose
The purpose of this study is to test the efficacy combining a treatment for depression with a treatment for alcohol dependence.
| Condition | Intervention | Phase |
|---|---|---|
|
Alcoholism Depression |
Drug: NALTREXONE Drug: Placebo |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Efficacy Study |
| Official Title: | The Treatment of Late Life Major Depression Complication by Alcohol |
| Enrollment: | 74 |
| Study Start Date: | October 1999 |
| Study Completion Date: | January 2005 |
| Primary Completion Date: | January 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Naltrexone
|
Drug: NALTREXONE |
|
2: Placebo Comparator
Placebo
|
Drug: Placebo |
This study aims to study 80 patients with comorbid alcohol dependence and a depressive syndrome. After appropriate detoxification, patients are started on either naltrexone 50 mg or placebo. After one week, sertraline is added in an open label fashion. It is hypothesized that those patients receiving combination therapy will last 3 months with follow-up tracking lasting 1 year.
Eligibility| Ages Eligible for Study: | 55 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Pennsylvania | |
| University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Principal Investigator: | David W. Oslin, MD | University of Pennsylvania |
More Information
| Responsible Party: | Department of Veterans Affairs ( Oslin, David - Principal Investigator ) |
| Study ID Numbers: | MHBS-009-98S |
| Study First Received: | July 3, 2001 |
| Last Updated: | September 21, 2009 |
| ClinicalTrials.gov Identifier: | NCT00018824 History of Changes |
| Health Authority: | United States: Federal Government |
|
Depression Narcotic Antagonists Physiological Effects of Drugs Disorders of Environmental Origin Depressive Disorder Pharmacologic Actions Behavioral Symptoms Sensory System Agents Mental Disorders |
Therapeutic Uses Alcoholism Naltrexone Substance-Related Disorders Mood Disorders Alcohol-Related Disorders Peripheral Nervous System Agents Central Nervous System Agents |